CLL | Tumor

CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.

Putting Life Into Perspective After a Cancer Diagnosis

December 19th 2018

Former NFL coach discusses how cancer motivated him to appreciate life.

Crossover Study Offers Additional Line of Therapy for Patients with Relapsed CLL/SLL

December 18th 2018

Single agent Copiktra (duvelisib) induced robust, durable responses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with Arzerra (ofatumumab).

Frontline BTK Inhibitor Regimen Improves Outcomes in CLL/SLL

December 14th 2018

Frontline use of Imbruvica (ibrutinib) in combination with Gazyva (obinutuzumab) significantly reduced the risk for disease progression or death among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), especially in those with high-risk disease.

Tackling Cancer With Purpose

December 8th 2018

This week, we spoke with former NFL coach, motivational speaker and acute promyelocytic leukemia survivor Chuck Pagano about his journey with cancer, and what has inspired him to give back following his diagnosis.

Curcumin and Vitamin D Treatment May Stabilize Disease in Patients with CLL and SLL

December 7th 2018

In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), high doses of curcumin and vitamin D could help stabilize the disease, according to new research presented at the American Society of Hematology’s (ASH) Annual Meeting in San Diego.

CAR-T Cell Therapy Combination Shows Promise in Relapsed/Refractory Leukemia

December 4th 2018

Administering Imbruvica with CAR-T cell therapy improved outcomes in patients with chronic lymphocytic leukemia, according to recent research.

Imbruvica Improves Outcomes in CLL, But Less Toxic Treatments Still Needed

December 3rd 2018

Regimens containing Imbruvica bested chemoimmunotherapy treatments in elderly patients with chronic lymphocytic leukemia, but less toxic and long-term treatments are still needed.

CLL Heroes Honored by CURE

December 3rd 2018

An oncologist and three advocates were honored for their work on behalf of people with chronic lymphocytic leukemia.

Setting the Stage for CAR-T Cell Therapy in Chronic Lymphocytic Leukemia

November 20th 2018

While CAR-T cell therapy has potential in treating CLL, T-cell fatigue and toxicity still raise many concerns.

Three Fast Facts on Chronic Lymphocytic Leukemia

November 19th 2018

CLL is the most common type of leukemia in adults across the United State. Here's what you need to know about the disease.

Cancer Drug Pricing Debate: Reducing Financial Burden Among Patients and Their Caregivers

November 18th 2018

What’s the best plan for lowering cancer drug prices? A panel of experts debated the possibilities.

Imbruvica Yields Favorable Safety Outcomes in Two Types of Lymphomas

November 12th 2018

Imbruvica (ibrutinib) is a safe treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), according to a pooled analysis of four clinical trials.

Taking the Long View

November 10th 2018

Chronic lymphocytic leukemia can now be managed as a long-term condition, and there are new ways loved ones can help.

Drug Duo Granted Priority Review for CLL Treatment

October 17th 2018

The FDA has granted a priority designation to a supplemental new drug application (sNDA) for Imbruvica (ibrutinib) for use in combination with Gazyva (obinutuzumab) for the frontline treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

FDA Approves Copiktra for Two Types of Blood Cancer

September 25th 2018

The drug was approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. And was granted an accelerated approval for follicular lymphoma.

What is CLL?

September 7th 2018

Equipping with knowledge to improve patient-physician communication and understanding the disease.

Chronic Lymphocytic Leukemia: A Patient-Centered Approach

August 26th 2018

An expert provides tips for maximizing time with your oncologist and adhering to oral medication.

Just the Facts

August 11th 2018

Better treatment options have put chronic lymphocytic leukemia in the spotlight in recent years. But just what is CLL?

Man Swims 22 Miles to Raise Money for Patients With Leukemia

July 30th 2018

Venclexta Combination Receives Full FDA Approval for CLL, With or Without 17p deletion

June 8th 2018

The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy.

Drug Duo Shows Promise in Treating Chronic Lymphocytic Leukemia

April 13th 2018

A new drug combination bested current standard of care in a clinical trial.

Duvelisib Granted Priority Review for CLL and Follicular Lymphoma

April 9th 2018

The Food and Drug Administration (FDA) granted duvelisib a priority review to a new drug application (NDA) for full approval to treat patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). The FDA also granted an accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.

Patients With CLL Are Willing to Trade Efficacy for Less Severe Side Effects

March 4th 2018

Survey finds quality of life and cost affect treatment decisions.

Combining and Sequencing Agents in CLL

January 30th 2018

William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).

CLL-Specific Society Fills Unmet Need

December 26th 2017

The CLL Society is a nonprofit organization that serves the CLL community by offering a platform for patients and caregivers to receive education and support, as well as information on cutting-edge research and treatment options.

CLL Survivors Worried About Life Expectancy, Quality of Life

December 25th 2017

While patients with chronic lymphocytic leukemia (CLL) tend to have long life expectancies, with many prescribed to a “watch-and-wait” approach, a recent study by the Cancer Support Community (CSC) found that more than half of patients living with the disease reported that having CLL affects their viewpoints regarding their life expectancy.

Examining the Safety of CLL Medication

September 25th 2017

OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include Imbruvica (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor; Venclexta (venetoclax), a B-cell lymphoma-2 (BCL2) inhibitor; and Zydelig (idelalisib), a phosphoinositide 3-kinase (PI3K) inhibitor.

Drug Provides High Response Rate in CLL

September 25th 2017

Venclexta (venetoclax), a BCL-2 inhibitor, had promising results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). According to an updated analysis of a clinical trial, the agent led to negative minimal residual disease (MRD) in 40 percent of patients involved.

A Personalized Era in Chronic Lymphocytic Leukemia Treatment

September 18th 2017

Researchers are identifying targets to treat chronic lymphocytic leukemia.

Expert Discusses Advances in Treating CLL

June 13th 2017

Imbruvica (ibrutinib) continues to demonstrate benefit in patients with chronic lymphocytic leukemia (CLL) who had at least one prior therapy, according to a four-year follow-up of the RESONATE study, which compared the BTK inhibitor to Arzerra (ofatumumab).